Search results for " Ulcerative Colitis"

showing 3 items of 43 documents

Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy.

2022

Abstract Background Adalimumab is used to treat ulcerative colitis, but additional effectiveness and safety data are needed. Patients and methods This retrospective study considered adults with ulcerative colitis treated with adalimumab at 19 hospitals. Clinical data were collected from the start of treatment, after 2, 6 and 12 months, and at the last visit. Outcome measures of effectiveness were treatment duration, reasons for discontinuation and colectomy. Results We studied 381 patients treated with adalimumab for a median of 12.1 months. Disease activity at the start of treatment was moderate to severe in 262 cases (68.8%) and endoscopic activity was moderate to severe in 339 cases (89.…

musculoskeletal diseasesAdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentEffectivenessYoung AdultInternal medicineAdalimumabMedicineHumansAdverse effectskin and connective tissue diseasesColectomyColectomyAgedRetrospective StudiesReal-world evidenceHepatologybusiness.industryGastroenterologyEffectiveneAdalimumabRetrospective cohort studyInduction ChemotherapyMiddle Agedmedicine.diseaseUlcerative colitisDiscontinuationClinical PracticeTreatment OutcomeUlcerative colitisItalyAdalimumab; Effectiveness; Real-world evidence; Safety; Ulcerative colitisConcomitantColitis UlcerativeFemaleTumor Necrosis Factor InhibitorsSafetybusinessmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analy…

2018

Abstract Background Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis. Aims We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis. Methods 118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up. Results Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in…

musculoskeletal diseasesModerate to severeAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaBiologicDisease durationAdalimumab; Biologics; Golimumab; Ulcerative colitis; Adalimumab; Adult; Antibodies Monoclonal; Colitis Ulcerative; Female; Humans; Italy; Logistic Models; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alphaUlcerativeBiologicsGolimumabSeverity of Illness IndexTreatment failureAntibodies03 medical and health sciences0302 clinical medicineInternal medicineMonoclonalAdalimumabmedicineHumansskin and connective tissue diseasesAdalimumab; Biologics; Golimumab; Ulcerative colitis; Hepatology; GastroenterologyPropensity ScoreProportional Hazards ModelsHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyAdalimumabAntibodies MonoclonalMiddle Agedmedicine.diseaseColitisUlcerative colitishumanitiesGolimumabLogistic ModelsTreatment OutcomeUlcerative colitisItaly030220 oncology & carcinogenesisPropensity score matching030211 gastroenterology & hepatologyColitis UlcerativeFemalebusinessmedicine.drug
researchProduct

Arthritis Associated with Ulcerative Colitis: Our Experience in Palermo

2009

To The Editor: Ulcerative colitis (UC) is one of the inflammatory bowel diseases, which affects the small intestine and colon [1]. The pathophysiology of UC is not known [2, 3]. The association between arthritis and UC is well known. The authors report the frequency of arthritis in 53 Sicilian patients with UC. The diagnosis of UC was made according to criteria described by Schachter and Kirsner [4]. The involvement of sacroilitic joints was assessed radiologically according to Bennett and Burch grade (0=normal joint, 1=suspicious sacroiliitis 2=abnormal joint with sclerosis and/or erosions, 3=unequivocally abnormal with erosions, sclerosis, widening or narrowing or partly ankylosed, 4=tota…

musculoskeletal diseasesmedicine.medical_specialtylcsh:MedicineArthritisLetter to EditorGastroenterologyInternal medicineSettore MED/33 - Malattie Apparato LocomotoremedicineAnkylosisRheumatoid factorSpondylitisHLA-B27Inflammatory bowel diseases Arthritis spondylitis ulcerative colitisbusiness.industryArthritislcsh:RSacroiliitisGeneral MedicineInflammatory Bowel Diseasesmedicine.diseaseUlcerative colitisSurgerymedicine.anatomical_structureUlcerative colitisAnklebusinessSpondylitisLibyan Journal of Medicine
researchProduct